Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 November 2024 | Story André Damons | Photo André Damons
Khoebo Innovation Promotion Programme launch 2024
Staff members from the Directorate Research Development (DRD) at the University of the Free State; Palesa Mgaga, second from right, Tebogo Machethe, centre, and Charelise van Staden, second from right, were thanked for hosting the launch of the Khoebo Innovation Promotion Programme. They are pictured with colleagues from the IDC’s Samkelisiwe Mtsewu, left, and Thato Mogopodi, far right.

The University of the Free State (UFS), represented by the Directorate Research Development (DRD), played host to the Department of Trade Industry and Competition (dtic) and the Industrial Development Corporation (IDC) for the launch of its Khoebo Innovation Promotion Programme (KIPP).

The launch took place on 5 November in the Sasol Library on the Bloemfontein Campus. Tebogo Machethe, Director: Research Contracts and Innovation at the DRD, said its role was to expose the university researchers to different opportunities and programmes for funding from the IDC and the dtic. It also allowed the researchers to engage potential funders in order to understand what funders look for in a project when considering funding it.

“The aim of IDC KIPP is to assist local entrepreneurs and small to medium enterprises with commercialisation funding. The KIPP offers capital and business support to SMMEs during the early stages of commercialisation with particular emphasis on township and rural entrepreneurs,” said Machethe.

Address uneven distribution of economic development

KIPP is a dtic programme but is managed by the IDC and aims to enable early-stage innovative SMEs to penetrate the market with their locally developed innovations, resulting in a more competitive economic environment and thereby facilitating economic growth in the economy.

According to Machethe, who welcomed the guests, participants and presenters to the launch, some of the funding is geared towards the development of university innovations. Though the focus was on the KIPP launch, he continued, the discussions also encompassed other forms of funding that are available and more geared towards the university innovation.

His address was centred around the university's Vision 130 and how it supports innovation and the entire innovation ecosystem, which seeks to shift the emphasis to research impact, embracing both knowledge and societal impact. Vision 130 identifies the need for a greater focus on collaborative research, research that can attract large-scale funding in niche areas where the university is seen as a national and global leader.

Samkelisiwe Mtsewu, KIPP Account Manager at the IDC, said the programme was introduced to address the uneven distribution of economic development across the country. She said with its capacity, the KIPP programme can contribute to addressing the uneven distribution of economic development. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept